Search

Supplemental material, sj-docx-3-ctj-10.1177_17407745231164569 for Determining the sample size for a cluster-randomised trial using knowledge elicitation: Bayesian hierarchical modelling of the intracluster correlation coefficient by Svetlana V Tishkovskaya, Chris J Sutton, Lois H Thomas and Caroline L Watkins in Clinical Trials

Supplemental material, sj-docx-5-ctj-10.1177_17407745231164569 for Determining the sample size for a cluster-randomised trial using knowledge elicitation: Bayesian hierarchical modelling of the intracluster correlation coefficient by Svetlana V Tishkovskaya, Chris J Sutton, Lois H Thomas and Caroline L Watkins in Clinical Trials

Supplemental material, sj-docx-1-ctj-10.1177_17407745231164569 for Determining the sample size for a cluster-randomised trial using knowledge elicitation: Bayesian hierarchical modelling of the intracluster correlation coefficient by Svetlana V Tishkovskaya, Chris J Sutton, Lois H Thomas and Caroline L Watkins in Clinical Trials

Supplemental material, sj-docx-3-ctj-10.1177_17407745231164569 for Determining the sample size for a cluster-randomised trial using knowledge elicitation: Bayesian hierarchical modelling of the intracluster correlation coefficient by Svetlana V Tishkovskaya, Chris J Sutton, Lois H Thomas and Caroline L Watkins in Clinical Trials

Supplemental material, sj-docx-1-wso-10.1177_17474930231164892 for Stroke in Sierra Leone: Case fatality rate and functional outcome after stroke in Freetown by Daniel Youkee, Gibrilla F Deen, Mamadu Baldeh, Zainab F Conteh, Julia Fox-Rushby, Musa Gbessay, Jotham Johnson, Peter Langhorne, Andrew JM Leather, Durodami R Lisk, Iain J Marshall, Jessica O’Hara, Sahr Pessima, Anthony Rudd, Marina Soley-Bori, Melvina Thompson, Hatem Wafa, Yanzhong Wang, Caroline L Watkins, Christine E Williams, Charles DA Wolfe and Catherine M Sackley in International Journal of Stroke

Supplemental material, sj-docx-4-ctj-10.1177_17407745231164569 for Determining the sample size for a cluster-randomised trial using knowledge elicitation: Bayesian hierarchical modelling of the intracluster correlation coefficient by Svetlana V Tishkovskaya, Chris J Sutton, Lois H Thomas and Caroline L Watkins in Clinical Trials

Supplemental material, sj-docx-4-ctj-10.1177_17407745231164569 for Determining the sample size for a cluster-randomised trial using knowledge elicitation: Bayesian hierarchical modelling of the intracluster correlation coefficient by Svetlana V Tishkovskaya, Chris J Sutton, Lois H Thomas and Caroline L Watkins in Clinical Trials

Supplemental material, sj-docx-5-ctj-10.1177_17407745231164569 for Determining the sample size for a cluster-randomised trial using knowledge elicitation: Bayesian hierarchical modelling of the intracluster correlation coefficient by Svetlana V Tishkovskaya, Chris J Sutton, Lois H Thomas and Caroline L Watkins in Clinical Trials

Supplemental material, sj-pdf-2-ctj-10.1177_17407745231164569 for Determining the sample size for a cluster-randomised trial using knowledge elicitation: Bayesian hierarchical modelling of the intracluster correlation coefficient by Svetlana V Tishkovskaya, Chris J Sutton, Lois H Thomas and Caroline L Watkins in Clinical Trials

Additional file 3. Effectiveness of QICs.

Additional file 1. PRISMA 2009 Checklist.

Additional file 2: Table S1. Likelihood of undertaking oral care assessments in the UK and in Australia. Categories unsure, not applicable and no response have been omitted. Table S2. Patient factors reported to influence whether an oral care assessment was undertaken for the UK and Australia. Categories unsure and no response have been omitted. Table S3. Staff factors, organisational factors and patient factors reported to influence oral care provision in the UK and Australia. Categories unsure and no response have been omitted. Figure S1. Oral care products available in UK (left) and Australian (right) hospitals.

Additional file 1: Supplementary Table 1: The twelve counts generated by the complex DTA design for a reported symptom. Supplementary Table 2: The two 2x2 marginal tables obtained by summation of the observed counts. Supplementary Table 3: Unadjusted odds ratio (OR) for key indicator symptoms.

Additional file 1.

Supplemental material, sj-pdf-1-wso-10.1177_17474930211027834 for Stroke in India: A systematic review of the incidence, prevalence, and case fatality by Stephanie P Jones, Kamran Baqai, Andrew Clegg, Rachel Georgiou, Harris Cath, Emma-Joy Holland, Yogeshwar Kalkonde, Catherine E Lightbody, Pallab BK Maulik, Padma MV Srivastava, Pandian J Durai, Patel Kulsum, PN Sylaja, Caroline L Watkins, Hackett Maree L and on behalf of the NIHR Global Health Research Group on IMPROVIng Stroke carE in India (IMPROVISE) Collaboration in International Journal of Stroke

Supplemental material, sj-pdf-1-wso-10.1177_17474930211027834 for Stroke in India: A systematic review of the incidence, prevalence, and case fatality by Stephanie P Jones, Kamran Baqai, Andrew Clegg, Rachel Georgiou, Harris Cath, Emma-Joy Holland, Yogeshwar Kalkonde, Catherine E Lightbody, Pallab BK Maulik, Padma MV Srivastava, Pandian J Durai, Patel Kulsum, PN Sylaja, Caroline L Watkins, Hackett Maree L and on behalf of the NIHR Global Health Research Group on IMPROVIng Stroke carE in India (IMPROVISE) Collaboration in International Journal of Stroke

Additional file 2. Search terms.

Supplemental material, WSO908140 Supplemental material for Prognostic significance of early urinary catheterization after acute stroke: Secondary analyses of the international HeadPoST trial by Menglu Ouyang, Laurent Billot, Lili Song, Xia Wang, Christine Roffe, Hisatomi Arima, Pablo M Lavados, Maree L Hackett, Verónica V Olavarría, Paula Muñoz-Venturelli, Sandy Middleton, Octavio M Pontes-Neto, Tsong-Hai Lee, Caroline L Watkins, Thompson G Robinson and Craig S Anderson in International Journal of Stroke

Supplemental material, Research Data1 for Establishment of an internationally agreed minimum data set for acute telestroke by Dominique A Cadilhac, Kathleen L Bagot, Bart M Demaerschalk, Gordian Hubert, Lee Schwamm, Caroline L Watkins, Catherine Elizabeth Lightbody, Joosup Kim, Michelle Vu, Nancy Pompeani, Jeffrey Switzer, Juanita Caudill, Juan Estrada, Anand Viswanathan, Nikolai Hubert, Robin Ohannessian, David Hargroves, Nicholas Roberts, Timothy Ingall, David C Hess, Annemarei Ranta, Vasantha Padma and Christopher F Bladin in Journal of Telemedicine and Telecare

Supplemental material, JTT899262 Supplemental Material2 for Establishment of an internationally agreed minimum data set for acute telestroke by Dominique A Cadilhac, Kathleen L Bagot, Bart M Demaerschalk, Gordian Hubert, Lee Schwamm, Caroline L Watkins, Catherine Elizabeth Lightbody, Joosup Kim, Michelle Vu, Nancy Pompeani, Jeffrey Switzer, Juanita Caudill, Juan Estrada, Anand Viswanathan, Nikolai Hubert, Robin Ohannessian, David Hargroves, Nicholas Roberts, Timothy Ingall, David C Hess, Annemarei Ranta, Vasantha Padma and Christopher F Bladin in Journal of Telemedicine and Telecare

Supplemental material, Research Data2 for Establishment of an internationally agreed minimum data set for acute telestroke by Dominique A Cadilhac, Kathleen L Bagot, Bart M Demaerschalk, Gordian Hubert, Lee Schwamm, Caroline L Watkins, Catherine Elizabeth Lightbody, Joosup Kim, Michelle Vu, Nancy Pompeani, Jeffrey Switzer, Juanita Caudill, Juan Estrada, Anand Viswanathan, Nikolai Hubert, Robin Ohannessian, David Hargroves, Nicholas Roberts, Timothy Ingall, David C Hess, Annemarei Ranta, Vasantha Padma and Christopher F Bladin in Journal of Telemedicine and Telecare

Supplemental material, WSO908140 Supplemental material for Prognostic significance of early urinary catheterization after acute stroke: Secondary analyses of the international HeadPoST trial by Menglu Ouyang, Laurent Billot, Lili Song, Xia Wang, Christine Roffe, Hisatomi Arima, Pablo M Lavados, Maree L Hackett, Verónica V Olavarría, Paula Muñoz-Venturelli, Sandy Middleton, Octavio M Pontes-Neto, Tsong-Hai Lee, Caroline L Watkins, Thompson G Robinson and Craig S Anderson in International Journal of Stroke

Supplemental material, Research Data3 for Establishment of an internationally agreed minimum data set for acute telestroke by Dominique A Cadilhac, Kathleen L Bagot, Bart M Demaerschalk, Gordian Hubert, Lee Schwamm, Caroline L Watkins, Catherine Elizabeth Lightbody, Joosup Kim, Michelle Vu, Nancy Pompeani, Jeffrey Switzer, Juanita Caudill, Juan Estrada, Anand Viswanathan, Nikolai Hubert, Robin Ohannessian, David Hargroves, Nicholas Roberts, Timothy Ingall, David C Hess, Annemarei Ranta, Vasantha Padma and Christopher F Bladin in Journal of Telemedicine and Telecare

Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight

Supplemental material, WSO873597 Supplemental Material for Moving stroke rehabilitation research evidence into clinical practice: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable by Janice J Eng, Marie-Louise Bird, Erin Godecke, Tammy C Hoffmann, Carole Laurin, Olumide A Olaoye, John Solomon, Robert Teasell, Caroline L Watkins and Marion F Walker: on behalf of the Bowell Group in International Journal of Stroke

BACKGROUND: Care home residents with stroke-related disabilities have significant activity limitations. Phase II trial results suggested a potential benefit of occupational therapy (OT) in maintaining residents' capacity to engage in functional activity. OBJECTIVE: To evaluate the clinical effectiveness and cost-effectiveness of a targeted course of OT in maintaining functional activity and reducing further health risks from inactivity for UK care home residents living with stroke-related disabilities. DESIGN: Pragmatic, parallel-group, cluster randomised controlled trial with economic evaluation. Cluster randomisation occurred at the care-home level. Homes were stratified according to trial administrative centre and type of care provided (nursing or residential), and they were randomised 1 : 1 to either the intervention or the control arm. SETTING: The setting was 228 care homes which were local to 11 trial administrative centres across England and Wales. PARTICIPANTS: Care home residents with a history of stroke or transient ischaemic attack, including residents with communication and cognitive impairments, not receiving end-of-life care. INTERVENTION: Personalised 3-month course of OT delivered by qualified therapists. Care workers participated in training workshops to support personal activities of daily living. The control condition consisted of usual care for residents. MAIN OUTCOME MEASURES: Outcome data were collected by a blinded assessor. The primary outcome at the participant level was the Barthel Index of Activities of Daily Living (BI) score at 3 months. The secondary outcomes included BI scores at 6 and 12 months post randomisation, and the Rivermead Mobility Index, Geriatric Depression Scale-15 and European Quality of Life-5 Dimensions, three levels, questionnaire scores at all time points. Economic evaluation examined the incremental cost per quality-adjusted life-year (QALY) gain. Costs were estimated from the perspective of the NHS and Personal Social Services. RESULTS: Overall, 568 residents from 114 care homes were allocated to the intervention arm and 474 residents from another 114 care homes were allocated to the control arm, giving a total of 1042 participants. Randomisation occurred between May 2010 and March 2012. The mean age of participants was 82.9 years, and 665 (64%) were female. No adverse events attributable to the intervention were recorded. Of the 1042 participants, 870 (83%) were included in the analysis of the primary outcome (intervention, n = 479; control, n = 391). The primary outcome showed no significant differences between groups. The adjusted mean difference in the BI score between groups was 0.19 points higher in the intervention arm [95% confidence interval (CI) -0.33 to 0.70, p = 0.48; adjusted intracluster correlation coefficient 0.09]. Secondary outcome measures showed no significant differences at all time points. Mean incremental cost of the Occupational Therapy intervention for residents with stroke living in UK Care Homes intervention was £438.78 (95% CI -£3360.89 to £1238.46) and the incremental QALY gain was 0.009 (95% CI -0.030 to 0.048). LIMITATIONS: A large proportion of participants with very severe activity-based limitations and cognitive impairment may have limited capacity to engage in therapy. CONCLUSION: A 3-month individualised course of OT showed no benefit in maintaining functional activity in an older care home population with stroke-related disabilities. FUTURE WORK: There is an urgent need to reduce health-related complications caused by inactivity and to provide an enabling built environment within care homes. TRIAL REGISTRATION: Current Controlled Trials ISRCTN00757750. FUNDING: This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 15. See the Health Technology Assessment programme website for further project information.

Background The occupational therapy (OT) in care homes study (OTCH) aims to investigate the effect of a targeted course of individual OT (with task training, provision of adaptive equipment, minor environmental adaptations and staff education) for stroke survivors living in care homes, compared to usual care. Methods/Design A cluster randomised controlled trial of United Kingdom (UK) care homes (n = 90) with residents (n = 900) who have suffered a stroke or transient ischaemic attack (TIA), and who are not receiving end-of-life care. Homes will be stratified by centre and by type of care provided and randomised (50:50) using computer generated blocked randomisation within strata to receive either the OT intervention (3 months intervention from an occupational therapist) or control (usual care). Staff training on facilitating independence and mobility and the use of adaptive equipment, will be delivered to every home, with control homes receiving this after the 12 month follow-up. Allocation will be concealed from the independent assessors, but the treating therapists, and residents will not be masked to the intervention. Measurements are taken at baseline prior to randomisation and at 3, 6 and 12 months post randomisation. The primary outcome measure is independence in self-care activities of daily living (Barthel Activities of Daily Living Index). Secondary outcome measures are mobility (Rivermead Mobility Index), mood (Geriatric Depression Scale), preference based quality of life measured from EQ-5D and costs associated with each intervention group. Quality adjusted life years (QALYs) will be derived based on the EQ-5D scores. Cost effectiveness analysis will be estimated and measured by incremental cost effectiveness ratio. Adverse events will be recorded. Discussion This study will be the largest cluster randomised controlled trial of OT in care homes to date and will clarify the currently inconclusive literature on the efficacy of OT for stroke and TIA survivors residing in care homes. Trial registration ISRCTN00757750